1-7 of 7
Praveen K. Tumula
Close
Sort by
Journal Articles

Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Initial Results from the Phase II Morningsun Study

Ian W. Flinn, L. Elizabeth Budde, Aung M. Tun, John M. Burke, Bertrand Anz, Shachar Peles, Jeff P. Sharman, Praveen K. Tumula, Juliana M. L. Biondo, Prachi Jani, Mei Wu, Tony Lin, Neha Parmar, Yong Mun, Nai-Shun Yao, Steven Liu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3029.
https://doi.org/10.1182/blood-2023-177917
Published: 2023
Journal Articles

Genomic Landscape of Ibrutinib- and/or Acalabrutinib-intolerant Patients with B-cell Malignancies Treated with Zanubrutinib in a Phase 2 Study

Linlin Xu, Mazyar Shadman, Ian W. Flinn, Moshe Levy, Ryan Porter, John M. Burke, Syed F. Zafar, Jennifer L. Cultrera, Jamal Misleh, Edwin C. Kingsley, Habte A. Yimer, Benjamin B. Freeman, Arvind Chaudhry, Praveen K. Tumula, Mitul Gandhi, Rocco J. Crescenzo, Kunthel By, Aileen Cleary Cohen, Adam Idoine, Sudhir Manda, Jeff P. Sharman
Journal: Blood
Blood (2023) 142 (Supplement 1): 6510.
https://doi.org/10.1182/blood-2023-180161
Published: 2023
Journal Articles

Genomic Characterization of Patients in a Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients with Relapsed/Refractory B-Cell Malignancies

Linlin Xu, Mazyar Shadman, Anusha Ponakala, Ian W. Flinn, Moshe Yair Levy, Ryan Porter, John M. Burke, Syed F. Zafar, Jennifer L. Cultrera, Jamal Misleh, Edwin C. Kingsley, Habte Yimer, Benjamin Freeman, Arvind Chaudhry, Praveen K. Tumula, Mitul Gandhi, Aileen Cohen, Dih-Yih Chen, Sudhir Manda, Jeff P. Sharman, Vanitha Ramakrishnan
Journal: Blood
Blood (2022) 140 (Supplement 1): 9269–9271.
https://doi.org/10.1182/blood-2022-167758
Published: 2022
Journal Articles

Drug Induced Thrombotic Microangiopathy Secondary to Quetiapine; The Second Reportable Case in Medical Literature

Mustafa Al-Bayati, Basheer U. Mohammed, Gnanashree Dharmarpandi, Kerolos Abdelmalek, Job Varghese, Praveen K. Tumula
Journal: Blood
Blood (2022) 140 (Supplement 1): 11354–11355.
https://doi.org/10.1182/blood-2022-164993
Published: 2022
Journal Articles

Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies

Mazyar Shadman, Ian W. Flinn, Moshe Y. Levy, Ryan Porter, John M. Burke, Jennifer L. Cultrera, Jamal Misleh, Syed F. Zafar, Benjamin Freeman, Subramanya S. Rao, Habte Yimer, Arvind Chaudhry, Mitul D. Gandhi, Troy H. Guthrie, Edwin Kingsley, Praveen K. Tumula, Sudhir Manda, Dih-Yih Chen, Aileen Cohen, Kunthel By, Linlin Xu, Ye Liu, Jeff P. Sharman
Journal: Blood
Blood (2021) 138 (Supplement 1): 1410.
https://doi.org/10.1182/blood-2021-148544
Published: 2021
Journal Articles

Atypical Chronic Myeloid Leukemia

Chandralekha Ashangari, MD, Praveen K. Tumula, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5455.
https://doi.org/10.1182/blood-2018-99-110189
Published: 2018
Journal Articles

Hairy Cell Leukemia Variant

Chandralekha Ashangari, MD, Divya Cheruku, MD, Praveen K. Tumula, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5562.
https://doi.org/10.1182/blood-2018-99-110192
Published: 2018